Teva Pharmaceutical Industries Limited
Market Cap
$35.04B
P/E Ratio
24.87
EPS
$1.21
Dividend Yield
0.00%
52-Week Range
$12.47 — $37.35
Volume
9.10M
Avg Volume
9.20M
Beta
0.72
P/E (TTM)
24.87
Forward P/E
11.13
PEG Ratio
0.26
P/S (TTM)
2.15
P/B (TTM)
4.66
P/FCF
26.31
EV/EBITDA
87.85x
EV/Sales
—
ROE (TTM)
0.20%
ROA (TTM)
0.03%
ROIC
0.05%
Gross Margin
0.52%
Operating Margin
0.18%
Net Margin
0.10%
Debt/Equity
2.20
Current Ratio
1.04
EPS Growth (YoY)
+3.23%
Revenue Growth (YoY)
+0.12%
EPS Growth (3Y)
+0.24%
EPS Growth (5Y)
-0.99%
Sales Growth (3Y)
+0.05%
Sales Growth (5Y)
+0.01%
EPS Est (This Year)
$2.70
EPS Est (Next Year)
$3.08
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$3.10
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $38.17(26.9% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
1.15B
Float
1.15B
Free Float %
99.98%
RSI (14)
71.35
SMA 20
$33.28
SMA 50
$31.45
SMA 200
$22.54
ATR (14)
1.12
Volatility (Week)
0.02%
Volatility (Month)
0.02%
Pattern
—
1 Day
-0.29%
1 Week
-5.19%
1 Month
+7.37%
3 Months
+43.39%
6 Months
+109.32%
1 Year
—
YTD
+11.05%
All-Time High
$37.35
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IL
Exchange
NYSE
IPO Date
1982-02-16
Employees
37000
CEO
Richard D. Francis
Index Membership
—
Website
https://www.tevapharm.com
Teva Pharmaceutical Industries Limited (TEVA) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NYSE. With a market capitalization of $35.04B, a P/E ratio of 24.87, TEVA is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare TEVA against other stocks using dozens of fundamental and technical filters.
Teva Pharmaceutical Industries Limited (TEVA) has a trailing twelve-month (TTM) P/E ratio of 24.87. This is near the market average range. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Teva Pharmaceutical Industries Limited (TEVA) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Teva Pharmaceutical Industries Limited (TEVA) has a market capitalization of $35.04 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Teva Pharmaceutical Industries Limited (TEVA) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $38.17 implies 26.9% upside from the current price.
Teva Pharmaceutical Industries Limited (TEVA) has returned +11.05% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.